Second-line Immunotherapy for ES-SCLC

Clinical trial NCT06853678 · RECRUITING

Trial details

NCT number: NCT06853678
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Start date: 2025-02-28
Primary completion: 2026-07-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.